Injectables
Is Jeuveau FDA Approved? Status, Indications, and the "Newtox" Positioning
Yes, Jeuveau is FDA approved for treating moderate to severe frown lines—and it's positioned as the first "Newtox" alternative to Botox.
Photo: ANVA Marketing / Pexels
AI Inside MedSpa Intelligence · Jun 26, 2026
FDA Approval Status
Yes, Jeuveau is FDA approved. The product received FDA clearance in February 2019 for the temporary improvement of moderate to severe glabellar lines (frown lines between the eyebrows) in adults. It is a botulinum toxin type A product, making it a direct competitor to Botox, Dysport, and Xeomin in the neurotoxin market.
What "Newtox" Means
Jeuveau is marketed as the first "Newtox"—a term coined to position it as a newer-generation botulinum toxin distinct from earlier formulations. While all four FDA-approved neurotoxins work via the same mechanism (blocking acetylcholine at the neuromuscular junction), Jeuveau's branding emphasizes its modern manufacturing process and clinical profile. For practice owners, this positioning helps differentiate the product in a crowded market and can support premium pricing or patient choice conversations.
Approved Indications
Jeuveau is currently approved only for glabellar lines—the vertical frown lines between the eyebrows. Like other neurotoxins, it is used off-label by many practices for forehead lines, crow's feet, and other dynamic wrinkles, but the FDA indication is limited to this one area.
What Practice Owners Should Know
Jeuveau received FDA clearance in February 2019 as the first "Newtox" botulinum toxin alternative to Botox.
Jeuveau is manufactured by Evolus, a company founded specifically to bring a new neurotoxin to market.
Dosing, onset, and duration are comparable to other botulinum toxin products, though individual patient response varies.
Verify current pricing, rebate programs, and supply agreements directly with your Evolus representative, as these change regularly.
Like all neurotoxins, Jeuveau requires proper credentialing, training, and informed consent protocols.
The "Newtox" positioning is marketing language; clinical efficacy and safety are comparable to established competitors.
For the latest regulatory updates or changes to approved indications, consult the FDA's official product database or contact Evolus directly.
Frequently asked questions
Is Jeuveau FDA approved for crow's feet and forehead lines?
Jeuveau is FDA approved only for glabellar lines (frown lines between the eyebrows). While many practices use it off-label for crow's feet and forehead lines, the official FDA indication is limited to that single area. Off-label use requires informed consent and proper documentation.
What is Newtox and how is Jeuveau different from Botox?
Newtox is marketing terminology positioning Jeuveau as a newer-generation botulinum toxin. All four FDA-approved neurotoxins (Botox, Dysport, Xeomin, and Jeuveau) work through the same mechanism—blocking acetylcholine at the neuromuscular junction. Jeuveau's distinction is its modern manufacturing process and branding, not fundamentally different clinical efficacy.
When did Jeuveau get FDA approval?
Jeuveau received FDA clearance in February 2019 for the temporary improvement of moderate to severe glabellar lines in adults. It was manufactured by Evolus, a company founded specifically to bring a new neurotoxin to market.
How does Jeuveau dosing compare to other botulinum toxins?
Jeuveau's dosing, onset, and duration are comparable to other botulinum toxin products like Botox and Dysport, though individual patient response varies. Verify specific dosing protocols and current pricing directly with your Evolus representative, as recommendations and rebate programs change regularly.
What training and credentialing do I need to inject Jeuveau?
Like all neurotoxins, Jeuveau requires proper credentialing, training, and informed consent protocols. Contact Evolus or your supplier for specific training requirements and ensure your staff completes any manufacturer-recommended education before administering the product.
Stay three moves ahead of every practice in your market.
Knowing it happened is table stakes. Inside MedSpa Pro hands you the play — what each move means for your margins, your license, and your patients, and exactly what to do about it — in a two-minute brief every morning. The owners who read it never get blindsided.
Get the edge · $20/mo Join the owners who run ahead of the industry. Cancel anytime, one click.
